HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.

AbstractINTRODUCTION:
There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes (T2DM) and cardiovascular disease (CVD). These observations suggest that pharmacological strategies, which reduce inflammation, may be therapeutically useful in treating obesity, type 2 diabetes and associated CVD.
AREA COVERED:
The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-α (etanercept, infliximab, adalimumab), IL-1β (anakinra, canakinumab) and IL-6 (tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists.
EXPERT OPINION:
The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity.
AuthorsNathalie Esser, Nicolas Paquot, André J Scheen
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 24 Issue 3 Pg. 283-307 (Mar 2015) ISSN: 1744-7658 [Electronic] England
PMID25345753 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Inflammatory Agents
  • Insulin
Topics
  • Animals
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Cardiovascular Diseases (drug therapy, physiopathology, prevention & control)
  • Diabetes Mellitus, Type 2 (drug therapy, physiopathology, prevention & control)
  • Drug Design
  • Humans
  • Inflammation (complications, drug therapy)
  • Insulin (metabolism)
  • Insulin Resistance
  • Metabolic Syndrome (drug therapy, physiopathology, prevention & control)
  • Obesity (complications, drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: